Search results for " mammalian"

Article A Plastic Pipeline for Commercial Bioprocessing?
Jenifer Wheat, head of commercial development, mammalian and microbial manufacturing business unit, Lonza Pharma & Biotech, says, “There’s enough room for all the scales out there. It’s not going to b…

Article State of the Biopharmaceutical Industry: Lessons from 2018 Survey Data
Despite diverse genetic-engineering methods and host organisms being available, industry has clearly come to prefer and standardize on use of mammalian systems, particularly CHO. Many more efficient o…

Article The Challenge of Disruptive Technologies in Bioprocessing
Other drivers relate to gaps in process performance, for example, “the notorious weakness of harvesting technologies in the face of the ever-increasing biomass from highly productive mammalian cell cu…

Article Optimizing Late-Stage and Commercial Cell-Culture Processes
…ovel scaffolds, for example, and we continue to develop and refine our microbial platforms alongside mammalian. Whether these systems have the potential to disrupt the CHO hegemony for production of …

Article Putting Viral Clearance Capabilities to the Test
“Even though few model viruses represent the biophysical characteristics of a broad range of mammalian viruses of different virus families, they are still models prepared and kept under laboratory con…

Article Preclinical Evaluation of Product Related Impurities and Variants
Two case studies—one involving a microbial therapeutic product (granulocyte colony stimulating factor)—and other—a mammalian therapeutic monoclonal antibody (bevacizumab) have been used to illustrate …

Article N-Glycan Analysis of Biotherapeutic Proteins
…potentially immunogenic; it is found in biotherapeutic proteins probably due to the use of non-human mammalian cell lines and the use of animal-derived components of culture media (25). Appro…

Poster Development of DoE based fed-batch strategies for high-producing CHO cell cultures
Fed-batch culture is commonly employed to maximize cell and product concentrations in upstream mammalian cell culture processes. Typical standard platform processes rely on fixed-volume bolus feedin…

Article Speed and Flexibility Are Dual Goals for Biopharma Operations
The facilities, built in partnership with Cytiva, offer cGMP manufacturing based on mammalian cell culture technologies to meet customer demand for Phase II/III clinical trials. In addition, the singl…

Article Reconciling Sensor Communication Gaps
“We need to be in line with their thinking to increase their comfort in outsourcing with us,” says Atul Mohindra, PhD, head of mammalian process research and technology at Lonza.cleaning validation, a…

Previous PageNext Page